{
  "abstract": "Introducing [¹⁷⁷Lu]Lu-PSMA-617 into metastatic hormone-sensitive prostate cancer (mHSPC) raises questions about patient selection and treatment sequencing. This non-systematic narrative review examines PSMAddition alongside evidence on alternative treatments, prostate-specific membrane antigen (PSMA) imaging, safety, and subsequent therapy. In the peer-reviewed analysis, with a data cutoff of 13 January 2025, adding radioligand therapy to androgen-deprivation therapy and an investigator-selected androgen receptor pathway inhibitor improved radiographic progression-free survival (hazard ratio 0.72; 95% confidence interval 0.58-0.90). Overall survival was immature and did not meet the prespecified interim significance threshold (hazard ratio 0.84; 95% confidence interval 0.63-1.13). A subsequent non-peer-reviewed sponsor update supported the radiographic findings, although the updated analysis was not controlled for type I error and overall survival remained immature. Radioligand intensification increased grade ≥3 adverse events (51% versus 43%). Prespecified composite quality-of-life and pain endpoints showed no statistically significant differences, although their interpretation is limited by the inclusion of progression or death. Control-arm crossover after progression was optional. Direct mHSPC evidence is distinguished from contextual castration-resistant evidence. Neither a preferred hormonal partner nor superiority over docetaxel-containing triplet therapy has been established. A non-prescriptive five-domain framework integrates target expression, disease characteristics, patient fitness, subsequent treatment options, and delivery capacity to support multidisciplinary assessment.",
  "abstract_shown": true,
  "affiliations": [
    "Associazione O.R.A. ETS-Oncology Research Assistance, 84134 Salerno, Italy.",
    "School of Medicine, UniCamillus-Saint Camillus International University of Health Sciences, 00131 Rome, Italy."
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 2,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Carlo Buonerba"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Giuseppe Di Lorenzo",
      "orcid": "0000-0001-7414-1568"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/4bm4ce2vpnpyq.bib",
  "cited_by": 0,
  "doi": "10.3390/curroncol33100624",
  "fulltext_url": "https://europepmc.org/articles/PMC13703700",
  "id": "4bm4ce2vpnpyq",
  "issns": [
    "1198-0052",
    "1718-7729"
  ],
  "landing_url": "https://europepmc.org/article/MED/42930191",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RC254-282"
    ],
    [
      "openalex",
      "2740|Prostate Cancer Treatment and Research"
    ]
  ],
  "openalex": "W7222700647",
  "pdf_url": "https://europepmc.org/articles/PMC13703700?pdf=render",
  "pmcid": "PMC13703700",
  "pmid": "42930191",
  "published": "2026-10-16",
  "publisher": "MDPI AG",
  "ris": "https://research.draconitic.com/paper/4bm4ce2vpnpyq.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:22:01Z",
      "native_id": "MED:42930191",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42930191"
    },
    {
      "first_seen": "2026-10-31T14:21:26Z",
      "native_id": "07583a9b9d214b209daf4c69275592b2",
      "source": "doaj",
      "url": "https://doi.org/10.3390/curroncol33100624"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "lcc:RC254-282",
      "subfield": "oncology"
    }
  ],
  "title": "[¹⁷⁷Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.",
  "title_text": "[¹⁷⁷Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-31T14:21:26Z",
  "url": "https://research.draconitic.com/paper/4bm4ce2vpnpyq",
  "venue": "Current oncology (Toronto, Ont.)",
  "versions": []
}